UBS analyst Ashwani Verma raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $49.00 (from $45.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE